How sponsors can move from retrospective audit planning to continuous, risk-based, inspection-ready oversight
The US FDA’s recent Real-Time Clinical Trials (RTCT) initiative is another signal that clinical trial oversight is moving towards faster, more continuous and more data-enabled decision-making. The agency has announced initiation of two proof-of-concept (POC) clinical trials designed to report endpoints and data signals in real time, alongside a Request for Information (RFI) for a broader RTCT pilot program expected to launch this summer. This initiative represents a shift toward integrating continuous regulatory oversight through-out the clinical trial conduct rather than retrospective review of clinical trial data post study completion.
This direction is closely aligned with the expectations set out under ICH E6 (R3), where sponsors are required to apply quality assurance through-out clinical trials by implementing risk-based strategies to identify potential or actual causes of serious non-compliance with the protocol, GCP and/or applicable regulations to enable their corrective and preventive actions.
In practice, this requires sponsors to move beyond retrospective audit planning and towards a more structured model of continuous, risk-based data-enabled QA oversight.
From retrospective audit planning to data-enabled and independent risk-based QA oversight
Traditional audit planning has often relied on retrospective indicators: high recruitment, protocol deviations, screen failures, dropout rates or other operational triggers. These remain useful, but they are not sufficient on their own to identify inherent risks and anomalies within the clinical trial data for a truly risk-proportionate QA oversight.
The foundation of risk-based QA oversight is in the identification of risks to the critical-to-quality (CTQ) factors translating the same into measurable insights and interpreting the risk signals in real-time as they emerge through-out trial conduct.
In order to translate the risks to measurable insights, it is imperative to establish quality tolerance limits (QTLs) at the beginning of the trial and revise the same as new data and new risk signals emerge through-out trial conduct.
These risk signals should be available for review and interpretation to quality assurance, independent of operations and medical monitoring, in order to prioritize and conduct risk-based audits, as required by ICH E6 (R3).
Technology platforms for risk-based QA oversight
The centralized statistical monitoring (CSM) and risk-based quality management (RBQM) platforms can be customized to generate specific risk-signals relevant for QA oversight. Once customized, these can generate risk signals for QA to evaluate as the study progresses and new data becomes available.
Used appropriately, these methods help QA teams validate assumptions, identify outliers and build a stronger evidence base for risk-based audit planning. However, statistical outputs from these systems alone should not be treated as automatic decisions. They require expert review, documentation and clear escalation pathways.
Dashboards are not enough
As clinical trial oversight becomes more data-enabled, sponsors should avoid reducing the discussion to dashboards alone. Visualization can be useful, but dashboards are not the same as compliant QA processes.
In a GCP-regulated environment, systems and processes used to inform oversight decisions need appropriate access controls, versioning, documentation, traceability and audit trails. If a risk indicator influences audit planning, escalation or corrective action, teams need to understand how that indicator was calculated, which data were used, who reviewed it and what action was taken.
This transparency is essential for inspection readiness. It also helps maintain confidence that data-driven oversight decisions are consistent, defensible and aligned with the sponsor’s quality management system.
Why this matters for small and mid-sized sponsors
The move toward data-enabled oversight is especially relevant for small and mid-sized sponsors. These organizations may rely heavily on CROs for trial execution, but sponsor oversight responsibilities remain with the sponsor.
When trial data are generated, processed or reported through outsourced operational models, independent QA perspective becomes particularly important. Sponsors need confidence that risk signals are being interpreted appropriately, that escalation pathways are clear and that oversight decisions are documented in a way that can withstand regulatory inspection.
How ADAMAS Consulting can support sponsors
ADAMAS Consulting supports sponsors in designing and implementing risk-based QA oversight models that connect clinical trial data, quality risk management and inspection readiness.
Our approach helps sponsors define CTQs and QTLs, translate risk into measurable indicators, prioritize audit activity, evaluate emerging risk signals and maintain documented, traceable decision-making. This combines deep GCP and QA expertise with data-enabled risk intelligence, helping sponsors move from retrospective checks to continuous, risk-proportionate QA oversight.
As regulatory expectations and industry practice move toward more timely access to clinical trial signals, sponsors need QA models that are not only data-enabled, but also compliant, expert-led and inspection-ready.
